Skip to main
CYRX
CYRX logo

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 56%
Buy 19%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc. demonstrated an improvement in financial performance, highlighted by an operating margin of (23.4%), which reflects a significant increase of 1,210 basis points year-over-year, surpassing consensus expectations. The company's revenue reached $59.5 million, marking a growth of 4.2% on a constant currency basis, supported by a notable increase in commercial revenue of 37% year-over-year. Additionally, the Life Sciences Products segment reported $20 million in revenue, improving from a prior decline to exceed consensus estimates, further reinforcing a positive outlook as the commercialization of cell and gene therapies is anticipated to drive future revenue growth.

Bears say

CryoPort Inc. has demonstrated a deceleration in revenue growth across its BioLogistics Solutions and BioStorage/BioServices segments, with overall Life Sciences Services revenue growth declining from 9% to 7% in the recent quarter. The company faces significant challenges due to anticipated slower cell and gene therapy approvals, which are expected to negatively impact its margins and profitability. Additionally, increased competition in the cold-chain logistics market further undermines the attractiveness of CryoPort's fundamentals, contributing to a negative outlook on the stock.

CryoPort (CYRX) has been analyzed by 16 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 19% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 16 analysts, CryoPort (CYRX) has a Buy consensus rating as of Jun 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.